Through a pay-back scheme organized in collaboration with Limburg’s Kankerfonds, InnoSer has recently acquired two new imagers that will enable deeper insights into our in vitro and in vivo platforms available for preclinical oncology research. The first being the ImageXpress Micro 4, a high-content, live cell imaging solution, and the second is the Lumina III In Vivo Imaging System which allows for bioluminescent imaging (BLI) of in vivo models.
ImageXpress Micro 4 –
Lumina III In Vivo Imaging System –
Want to read more?
Neurodevelopmental disorder mouse models at InnoSer — TSC, Rett & STXBP1
in this month's update, we invite you to explore recent developments in rare neurodevelopmental disorders associated with epilepsy and seizure phenotypes. We highlight emerging therapeutic approaches, discuss the importance of selecting translationally relevant...
Your compound has shown efficacy in a preclinical disease model – now what? Moving from exploratory studies to GLP toxicology studies
A practical guide to transitioning from exploratory studies to GLP toxicology when outsourcing your non-clinical safety program to a specialist GLP toxicology CRO.Demonstrating efficacy in a disease model represents a major milestone in preclinical drug development....
Plasma NfL, p-tau217, or Aβ42/40: Which Alzheimer’s disease biomarkers should you include in your preclinical efficacy study?
A practical guide to preclinical Alzheimer’s disease biomarkers panel selection when you’re considering outsourcing to a specialist neurology CRO Biomarkers have transformed Alzheimer's disease clinical trials, enabling diagnosis confirmation for trial eligibility,...